133 related articles for article (PubMed ID: 32588924)
1. Venetoclax Boosts Benefits of R-EPOCH in Aggressive B-Cell Lymphomas.
Oncologist; 2020 Jul; 25 Suppl 1(Suppl 1):S14-S15. PubMed ID: 32588924
[TBL] [Abstract][Full Text] [Related]
2. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.
Rutherford SC; Abramson JS; Bartlett NL; Barta SK; Khan N; Joyce R; Maddocks K; Ali-Shaw T; Senese S; Yuan Y; Westin J; Leonard JP
Lancet Haematol; 2021 Nov; 8(11):e818-e827. PubMed ID: 34634256
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
Davids MS; Rogers KA; Tyekucheva S; Wang Z; Pazienza S; Renner SK; Montegaard J; Ihuoma U; Lehmberg TZ; Parry EM; Wu CJ; Jacobson CA; Fisher DC; Thompson PA; Brown JR
Blood; 2022 Feb; 139(5):686-689. PubMed ID: 34788401
[TBL] [Abstract][Full Text] [Related]
4. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
[TBL] [Abstract][Full Text] [Related]
5. Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma?
Lakhotia R; Melani C; Roschewski M; Wilson WH
J Clin Oncol; 2022 Jun; 40(18):2063-2064. PubMed ID: 35377729
[No Abstract] [Full Text] [Related]
6. Leukemic form of high-grade B-cell lymphoma (HGBL) in a very elderly patient with multiple comorbidities: effective treatment of a very rare subtype with a mini-R-da-EPOCH version.
Belia M; Drandakis I; Lakiotaki E; Arapaki M; Panitsas F; Triantafyllou EF; Plata E; Siakantaris MP; Angelopoulou MK; Korkolopoulou P; Vassilakopoulos TP
Ann Hematol; 2023 Aug; 102(8):2279-2282. PubMed ID: 37115296
[No Abstract] [Full Text] [Related]
7. Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma.
Samineni D; Huang W; Gibiansky L; Ding H; Zhang R; Li C; Sinha A; Rajwanshi R; Humphrey K; Bazeos A; Salem AH; Miles D
Adv Ther; 2022 Jan; 39(1):598-618. PubMed ID: 34822104
[TBL] [Abstract][Full Text] [Related]
8. CHOP plus rituximab--balancing facts and opinion.
Cheson BD
N Engl J Med; 2002 Jan; 346(4):280-2. PubMed ID: 11807154
[No Abstract] [Full Text] [Related]
9. Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience.
Qin S; Jiang R; Dai L; Miao Y; Sha Y; Qiu T; Ding C; Wang Z; Shi C; Xia Y; Fan L; Xu W; Li J; Zhu H
Ann Hematol; 2024 May; 103(5):1635-1642. PubMed ID: 38246951
[TBL] [Abstract][Full Text] [Related]
10. A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma.
Wilder DD; Ogden JL; Jain VK
Clin Lymphoma; 2001 Mar; 1(4):285-92. PubMed ID: 11707843
[TBL] [Abstract][Full Text] [Related]
11. Dose-adjusted EPOCH-R: a feasible alternative for Burkitt lymphoma in resource-constrained settings.
Jindal N; Jain A; Lad D; Prakash G; Khadwal A; Malhotra P
Br J Haematol; 2020 Sep; 190(6):e362-e363. PubMed ID: 32614462
[No Abstract] [Full Text] [Related]
12. Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma.
Coiffier B; Salles G
Blood; 2004 Sep; 104(5):1584-5; author reply 1585-6. PubMed ID: 15317734
[No Abstract] [Full Text] [Related]
13. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A
Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
[TBL] [Abstract][Full Text] [Related]
14. Dose-adjusted EPOCH-R in patients with newly diagnosed diffuse large B-cell lymphoma harboring MYC rearrangement.
Kojima M; Amaki J; Ogiya D; Ando K; Nakamura N
J Clin Exp Hematop; 2020 Jun; 60(2):60-61. PubMed ID: 32404573
[No Abstract] [Full Text] [Related]
15. Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma.
Knörr F; Zimmermann M; Attarbaschi A; Kabíčková E; Maecker-Kolhoff B; Ruf S; Kühnle I; Ebinger M; Garthe AK; Simonitsch-Klupp I; Oschlies I; Klapper W; Burkhardt B; Woessmann W
Haematologica; 2021 Dec; 106(12):3232-3235. PubMed ID: 34498443
[No Abstract] [Full Text] [Related]
16. MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R.
Lai C; Roschewski M; Melani C; Pittaluga S; Shovlin M; Steinberg SM; Dunleavy K; Pack S; Jaffe ES; Wilson WH
Leuk Lymphoma; 2018 Feb; 59(2):505-508. PubMed ID: 28641474
[No Abstract] [Full Text] [Related]
17. Therapy for older patients with diffuse large cell lymphoma: targeting the treatment to the patient.
Siegel AB; Leonard JP
Leuk Lymphoma; 2007 Feb; 48(2):225-6. PubMed ID: 17325880
[No Abstract] [Full Text] [Related]
18. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
19. Treatment of progression during reductive prophase for paediatric primary mediastinal B-cell lymphoma using dose-adjusted EPOCH chemotherapy.
Chen RL; Chuang SS; Lu YH
Pediatr Blood Cancer; 2011 Jul; 56(7):1149-50. PubMed ID: 21337677
[No Abstract] [Full Text] [Related]
20. Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma.
Avilés A; Neri N; Castañeda C; Talavera A; Huerta-Guzmán J; González M
Med Oncol; 2002; 19(1):55-8. PubMed ID: 12025891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
